STOCKS TELEGRAPH

Category: US Stocks

  • Why did Surgalign Holdings Inc. (SRGA) stock surge in the after-hours on Friday?

    Surgalign Holdings Inc. (SRGA) shares jumped 9.56% in after-hours on Friday, August 13, 2021, and closed the weekly trading at $0.99 per share. In the regular trading session of Friday, SRGA’s stock lost 1.02%. SRGA shares have fallen 65.86% over the last 12 months, and they have moved down 2.55% in the past week. Over the past three months, the stock has lost 39.91%, while over the past six months, it has shed 69.24%.

    Let’s discuss its recent news and developments.

    SRGA recent financial results announcement

    On August 06, 2021, Surgalign Holdings, Inc (SRGA) reported its financial results for the second quarter of 2021.

    Q2 2021 financial highlights

    • SRGA reported revenue of $24.8 million in Q2 2021 compared to $20.5 million in Q2 2020.
    • In Q2 2021, the company made a gross profit of $17.6 million compared to $11.1 million in Q2 2020.
    • Total operating expenses were $30.88 million compared to $36.18 million in Q2 2020.
    • It suffered a net loss of $10.6 million in Q2 2021compared to $24.9 million for the second quarter of 2020.
    • Adjusted EBITDA was -$8.5 million inQ2 2021 compared -$21.4 million for the second quarter of 2020.
    • The company had cash and cash equivalents of approximately $70 million on June 30, 2021.

    FY 2021 revised financial guidance

    For FY 2021 company is now expecting

    • Revenue in the range of $95 million to $100 million.
    • Adjusted EBITDA loss in the range of $35 – $40 million.

    SRGA Inducement Grants

    On August 02, 2021, Surgalign Holdings, Inc. (SRGA) granted restricted stock unit awards to 10 employees, in the aggregate, up to 91,925 shares of Surgalign common stock.

    Earlier on July 1, 2021, the company granted restricted stock unit awards to nine employees, in the aggregate, up to 74,460 shares of Surgalign common stock.

    SRGA Participation in the recent investor conference

    Surgalign Holdings, Inc recently participated in the Sidoti Virtual Investor Conference which was held on Wednesday, June 23, 2021.

    SRGA closed registered directed offering of Common Stock

    On June 14, 2021, Surgalign Holdings, Inc closed its previously announced registered direct offering for the issuance and sale of an aggregate of 28,985,508 shares of its common stock and warrants to purchase up to an aggregate of 28,985,508 shares of its common stock at a purchase price of $1.725 per share of common stock and related warrant. The warrants have an exercise price of $1.725 per share.

    SRGA will get gross proceeds of approximately $50 million and intends to use the net proceeds from the offering for working capital and general corporate purposes.

    Conclusion

    As of this writing, we have no recent news that could be linked with its turnaround. We hope that it will continue its positive performance on Monday as well.

  • Here is why The Walt Disney Company (DIS) stock went up on Thursday?

    Here is why The Walt Disney Company (DIS) stock went up on Thursday?

    The Walt Disney Company (DIS) shares rose 5.63% in after-hours on Thursday, August 12, 2021, and closed at $189.38. Earlier in the regular trading session of Thursday, DIS’s stock gained 0.67%. DIS shares have risen 36.04% over the last 12 months, and they have moved up 1.46% in the past week. Over the past three months, the stock has gained 0.53%, while over the past six months, it has declined 6.09%.

    Let’s discuss its recent news and developments

    DIS recent financial results announcement

    On August 12, 2021, The Walt Disney Company (DIS) released earning details for its third fiscal quarter ended July 3, 2021.

    Q3 2021 financial highlights

    • DIS reported revenue of $17,022 million in Q3 2021 compared to $11,779 in Q3 2020.
    • It reported a net loss of $923 million in Q3 2021 compared to a net loss of $1,864 in Q3 2020.
    • Diluted earnings per share were $0.50 in Q3 2021 compared to a loss of $2.61 in the prior-year quarter.
    • The company had a free cash flow of $528 million in Q3 2021 compared to $454 million in Q3 2020.

    DIS re-launched annual passes

    DIS relaunched its 37-year-old annual pass program to help reduce crowding on high-demand days with a twist. Now Disney annual passes starting at $399 a year for Southern California residents, with price tiers at $649, $949, and $1,399 for all guests. Unlike the old program, Magic Key holders will need to make advance park reservations.

    More information will be released soon about the passes.

    DIS Jungle Cruise Top-Notch performance

    The Walt Disney Company’s (DIS) “Jungle Cruise” reigned at the weekend U.S. box office with $34.1 million in ticket sales from a 4,310-screen engagement.

    Mandatory vaccination for DIS U.S employees

    On July 31, 2021, Walt Disney Company (DIS) made vaccination mandatory for all its on-site salaried and non-union hourly employees in the United States, as the highly infectious Delta COVID-19 variant drives a resurgence in cases.

    The DIS new feature attraction

    Disney+ introduced a new series on July 22, 2021, “Behind the Attraction” with every episode looking at the origin of popular theme park attractions.

    The stakes will be raised even higher when Jungle Cruise hits theatres next week. The film, starring Dwayne Johnson and Emily Blunt, is named and themed loosely for the classic pun-laden Disneyland boat ride.

    Conclusion

    DIS stock went up after the company announced its Q3 financial results which impressed the investors. Exceptional user growth would be a catalyst in the coming days for its Stock surging.

  • Why ContextLogic Inc (WISH) stock plummeted on Thursday?

    ContextLogic Inc. (WISH) shares declined 20.09% in after-hours on Thursday, August 12, 2021, and closed the daily trading at $7.52 per share. In the regular trading session, WISH’s stock lost 4.27% as well. WISH shares have moved down 5.71% in the past week. Over the past three months, the stock has gained 16.03%, while over the past six months, it has lost 66.49%. Further, the company has a current market of $5.91 billion and its outstanding shares stood at 619.00 million.

    Let’s see what’s going on with the company?

    WISH latest financial results announcement

    On August 12, 2021, ContextLogic Inc (WISH) reported financial results for its second quarter ended June 30, 2021.

    Q2 2021 financial highlights

    • WISH reported revenue of $656 million in Q2 2021 compared to $701 million in Q2 2020.
    • In Q2 2021, gross profit was $384 million compared to $493 million in Q2 2020.
    • The cost of revenue for the second quarter of 2021 was $272 million compared to $208 million in Q2 2020.
    • It suffered a net loss of $111 million in Q2 2021 compared to an $11 million net loss in Q2 2020.
    • Adjusted EBITDA was $67 million in Q2 2021 compared to $16 million in Q2 2020.
    • As of June 30, 2021, the company had $1.6 billion in cash, cash equivalents and marketable securities.

    WISH made new appointments

    On August 02, 2021, ContextLogic Inc (WISH), appointed Tarun Jain, former product leader from Google, to the newly created position of Chief Product Officer. Mr Jain will report directly to Wish Founder and CEO, Piotr Szulczewski, effective immediately.

    Earlier, the company appointed Farhang Kassaei, former Senior Director at Google, to the newly created position of Chief Technology Officer, effective July 12, 2021.

    WISH new Payment Services License in Europe

    On July 06, 2021, ContextLogic B.V. which is a Dutch subsidiary of ContextLogic Inc (WISH) was granted a Payment Services License by the Dutch Central Bank.

    The new Payment Services License will enable the company to process transactions and increase control over the payments value chain in a compliant manner, while also reducing reliance on third parties. In addition to the Netherlands, the license will be passported to the other European markets where Wish operates. Wish will initially utilize the license to pay its EU merchants directly and will explore other payment services in the future. The license will not have an impact on consumers in Europe.

    WISH CFO resignation

    ContextLogic Inc Chief Financial Officer Rajat Bahri resigned from the company effective July 23, 2021.

    Chief Accounting Officer Brett Just and Director of FP&A Jennifer Oliver will serve as interim co-CFOs, reporting directly to Executive Chair, Jackie Reses. Mr. Just and Ms. Oliver have been with Wish since 2017 and 2018, respectively.

    Conclusion

    WISH stock plummeted after the company was unable to announce appealing financial results for Q2 2021. The company is also facing some legal challenges and we hope that it will return towards positivity soon.

  • Here is why Zomedica Corp. (ZOM) stock underperformed on Wednesday?

    Zomedica Corp. (ZOM) shares declined 10.85% in after-hours on Wednesday, August 11, 2021, and closed the daily trading at $0.50 per share. In the regular trading session on Wednesday, ZOM’s stock lost 2.76%. ZOM shares have risen 270.39% over the last 12 months, and they have moved down by 2.60% in the past week. Over the past three months, the stock has lost 27.37%, while it has slid down 77.92% over the past six months.

    Let’s have a look at its recent news and developments.

    ZOM recent financial results

    On Aug. 11, 2021, Zomedica Corp. (ZOM) announced consolidated financial results for the three and six months ended June 30, 2021.

    Q2 2021 financial highlights

    • ZOM reported revenue of $15,693 for Q2 2021.
    • It suffered a net loss of approximately $4.7 million or $.005 per share in Q2 2021 compared to a net loss of approximately $5.3 million, or $0.02 per share, for Q2 2020.
    • The cost of revenue for the three and six months ended June 30, 2021, was $35,876.
    • Research and development expense for the three months ended June 30, 2021, was approximately $0.3 million compared to approximately $3.9 million for Q2 2020.
    • Selling, general and administrative expenses were approximately $5.0 million in Q2 2021, compared to approximately $1.4 million for the three months ended June 30, 2020.
    • As of June 30, 2021, the company had cash and cash equivalents of approximately $276.2 million compared to approximately $29.1 million as of June 30, 2020.

    ZOM 2021 AGM results

    On July 30, 2021, Zomedica Corp. (ZOM) announced the voting results of its 2021 Annual Virtual-Only Meeting of Shareholders which was held on July 30, 2021.

    At the meeting, the Company’s shareholders approved all items of business.

    ZOM Corporate update

    On July 06, 2021, Zomedica Corp (ZOM) provided the following corporate update.

    Zomedica’s flagship product, TRUFORMA is intended to have five initial assays to test for adrenal and thyroid disorders, which will be followed by many more assays to address other disease states. Three of the initial assays (TSH, tT4, and Cortisol) currently are available.

    The fT4 assay is expected to be available for commercial sale in the late September / early October time frame, with ACTH following about two months later.

    New appointments

    On May 17, 2021, Zomedica Corp. (ZOM) hired a Vice President of Business Development to lead its acquisition and licensing efforts. Greg Blair joined the Company as Vice President of Business Development, becoming a senior executive team member reporting to Mr. Cohen.

    Conclusion

    ZOM shares declined after the company reported its financial results which are not very appealing for the customers. We can expect it to decline further in the coming trading session.

  • Why NexPoint Strategic Opportunities Fund (NHF) stock pop up on Friday?

    NexPoint Strategic Opportunities Fund (NHF) shares surged 5.53% in the after-hours on Friday, August 06, 2021, and closed the weekly trading at $14.15 per share. In the regular trading on Friday, NHF’s stock gained 0.83%. NHF shares have risen 44.19% over the last 12 months, and they have moved down1.69% in the past week. Over the past three months, the stock has gained 11.75%, while over the past six months, it has declined 19.41%.

    Let’s have a look at its recent developments.

    NHF extend the Purchase offer of UDFI shares

    On August 05, 2021, NexPoint Strategic Opportunities Fund (NHF) extended the offering period for its previously announced offer to purchase all Shares of Beneficial Interest of United Development Funding IV at $1.10 per share. The Offer is now scheduled to expire at midnight, Eastern Time, at the end of the day on September 2, 2021, unless the Offer is extended or earlier terminated.

    NHF declared July 2021 dividend

    On August 02, 2021, NexPoint Strategic Opportunities Fund (NHF) announced its regular monthly distribution on its common stock of $0.05 per share. The distribution will be payable on August 31, 2021, to shareholders of record at the close of business on August 24, 2021.

    NHF Won Claims against Credit Suisse

    On June 28, 2021, The NexPoint Strategic Opportunities Fund (NHF) provided an update in the case against Credit Suisse, AG, Cayman Islands Branch, and Credit Suisse Securities (USA), LLC (Credit Suisse).

    The 134th Judicial District Court issued a judgment today against Credit Suisse, awarding $121 million to Claymore Holdings LLC, the entity formed to pursue the collective claims on behalf of NHF and the Highland Income Fund.

    The Court said that as a result of the Texas Supreme Court’s April 2020 ruling, which upheld the prior findings that Credit Suisse committed fraud but remanded the case to the trial court to enter a new damages award.

    Credit Suisse has thirty days to file for an appeal of the judgment. The total aggregate award, which stands at $121 million today, consists of damages and prejudgment interest.

    Conclusion

    We only had one recent news that may or may not be the reason behind its exceptional performance on Friday. we hope that NHF will commence the new week with the same positive trend of Friday.

  • Why did Intrusion Inc. (INTZ) stock skyrocket on Tuesday?

    Intrusion Inc. (INTZ) shares declined 4.67% in after-hours on Tuesday, July 27, 2021, and closed the daily trading at $4.90 per share. Earlier in the regular trading session of Tuesday, INTZ’s stock gained 52.07%. INTZ shares have fallen 44.19% over the last 12 months, and they have moved up by 20.66% in the past week. Over the past three months, the stock has lost 71.51%, while over the past six months, it has declined 78.57%. The company has a current market of $96.68 million and its outstanding shares stood at 17.54 million.

    Let’s see is there any recent news behind its massive surge on Tuesday?

    INTZ preliminary Q2 2021 financial figures

    On July 20, 2021, INTRUSION, Inc. (INTZ) announced preliminary revenue for the second quarter of 2021, which is expected to be within the range of $1.9 million and $2.0 million.

    Upcoming Financial results announcement

    INTRUSION will announce its full second-quarter results on Thursday, August 12, and host a conference call with Anthony LeVecchio, Chairman of the Board, and Messrs. Byrd and Head participating at 4:00 p.m. Central Time.

    INTZ arranging more funding

    INTRUSION also said that additional capital may be required to achieve profitability. Recently, INTZ has engaged an investment banking firm to evaluate various funding sources, and also potentially constructive longer-term strategic options that might help INTRUSION grow, achieve its operating objectives, and maximize shareholder value.

    INTZ Organizational Changes

    INTZ also made some changes to its management and the Board of Directors of INTRUSION has asked CFO, Franklin Byrd, and CTO, Joe Head–who is also an INTRUSION Co-Founder–to assume operating responsibilities together on behalf of the Company immediately. The changes were made after Jack B. Blount, previously President, Chief Executive Officer and a Board member left the company.

    INTZ inauguration on Russell Microcap® Index

    INTRUSION, Inc(INTZ) joined the Russell Microcap® Index on June 25, 2021, according to a preliminary list of additions published by FTSE Russell on June 4, 2021.

    Intrusion facing several lawsuits

    Intrusion has been dragged into court by many reputable law firms in America and filed several lawsuits against the company.

    Rosen Law Firm filed a lawsuit against INTZ and reminded purchasers of the securities of Intrusion Inc between January 13, 2021, and April 13, 2021.

    According to the lawsuit, the Company made false and misleading statements to the market. Intrusion’s Shield product was not an innovative new offering, but rather the repackaging of existing technology.

    Conclusion

    Well, as of this writing, there is no recent news that could justify the INTZ surge and later its decline. We are unable to predict how it will perform in the coming days.

  • What Is Driving The UBX Stock Higher In Early Trades?

    In the current market at the time of writing, Unity Biotechnology Inc. (UBX) shares were trading at $4.71, up 5.37%. The UBX stock price closed at $4.47 in the previous session. Volume on UBX stock fell to 0.47 million shares, less than the 50-day average of 0.55 million shares. Within the past week, UBX shares have risen by 3.00%, following a drop of -50.11% over the past 12 months.

    UBX stock has lost -27.79% over the past three months, and -14.69% over the past six months. Furthermore, UBX has a market capitalization of $246.79 million and 54.17 million outstanding shares. Following a positive phase I clinical trial announcement, UBX stock is rising.

    What is the purpose of UBX’s trial?

    A new class of therapeutics is being developed by UNITY to prevent, slow down, or reverse diseases of aging. UBX is currently developing medicines that target senescent cells which will have a transformative effect on diseases related to aging.

    A Phase 1 safety study of UBX1325 involving a combination of vegf inhibitors and monoclonal antibodies was announced today by Unity Biotechnology for early-stage DME or wet AMD patients for whom anti-VEGF treatment was no longer considered effective.

    • As part of UBX’s Phase 2a clinical study, the first patient with DME has been dosed with UBX1325.
    • UBX anticipates receiving trial results in the first half of 2022.
    • A Phase 1 study with advanced wet AMD is also being conducted by UBX so that more data can be collected to support a Phase 2a study in wet AMD.
    • It is hoped that the results of these studies will inform clinicians about UBX1325’s efficacy across a wider spectrum of patients, including those who are refractory to anti-VEGF therapy.
    • Twelve patients with advanced DME or wet AMD, unresponsive to anti-VEGF therapies, were included in the UBX Phase 1, first-in-human, open-label study.
    • These results support further clinical development of UBX1325 in this patient population, which showed a favorable acute safety profile.
    • Two nonserious but nondrug-related adverse events were reported, but no dose-limiting toxicity was observed.
    • Further, patients treated with UBX1325 saw improvement in sight and retinal structure.

    What UBX is expecting further?

    Unity Biotechnology (UBX) candidate works entirely differently, by targeting a completely different mechanism in the retinal and choroidal vasculature, which is a possible root cause of disease progression. With this method, UBX1325 would be a valuable alternative to anti-VEGF treatments. In the coming year, Unity (UBX) will be reporting a number of important data readouts that will bolster its knowledge of the optimal treatment regimen and combination of UBX1325 and DME.

  • Staffing 360 Solutions, Inc. (STAF) Stock Skyrockets Following Announcement of Reverse Stock Split

    Staffing 360 Solutions, Inc. (STAF) stock prices were down by 7.43% as of the market closing on June 30th, 2021, bringing the price per share down to USD$0.5744 at the end of the trading day. Subsequent pre-market fluctuations saw the stock skyrocket by a staggering 552.86%, bringing it up to USD$3.75.

    Reverse Stock Split

    June 30th, 2021 saw the company announce its intent to implement a reverse stock split of its common stock at a ratio of 6 pre-split shares being consolidated into 1 post-split share. The stock split went into effect at 5:00 pm EDT on June 30th, 2021, with the company’s shares continuing to be traded on the NASDAQ Capital Market under the STAF ticker symbol. The shares will begin trading on a split-adjusted basis when the market opens on July 1st, 2021.

    Details of the Reverse Split

    The company’s Board of Directors were authorized to effect a reverse stock split on June 21st, 2021 at a special meeting of stockholders, with the amendment to the Certificate of Incorporation allowing for a ratio of at least 1-for-2 and not more than 1-for-20. While the stock split will not affect the percentage interest of any stockholder in the company’s equity, there will be cases where stockholders will own a fractional share. In such cases, the share will be rounded up to the nearest whole number of shares. The number of common stock outstanding will go from 39,166,528 to 6,527,755.

    Loan Forgiveness

    The company recent reported having been granted full forgiveness by the Small Business Administration for the USD$10 million Paycheck Protection Program loan. The loan was given to Monroe Staffing Services, LLC, an indirect wholly owned subsidiary of STAF. Since, the company has applied for further forgiveness of USD$9.4 million in PPP loans, with management confident in their being written off. Cumulatively, STAF has achieved a 55% reduction in its debt over the past year.

    Q2 2021 Financial Reports

    STAF forecasts financial reports for Q2 2021, ended July 3rd, 2021, to indicate roughly 20% year-over-year growth in revenue up to USD$52 million. Gross profits for the quarter are also expected to be up by 20%, with reports of USD$457,000 in operating profit as compared to USD$1.5 million operating loss in Q2 2020.

    Future Outlook for STAF

    With the drastic change seen by its stock price as a result of the reverse stock split, STAF is poised to capitalize on its continued listing on the Nasdaq Capital Market. Investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Tarena International Inc. (TEDU) stock plunged in the current trading session; here’s why

    Tarena International Inc. (TEDU) stock plunged in the current trading session; here’s why

    In the current trading session, at last check, Tarena International Inc. and TEDU stock had plunged by-13.79% trade at $2.75. TEDU stock previously closed the session at $3.19. The stock volume traded 1.08 million shares. TEDU stock has moved shed in the past week by -11.63%. In the past three and six months, the stock shed -6.18%, and-3.33% respectively. Furthermore, Tarena International Inc. is currently valued in the market at $189.10 million and has 55.67 million outstanding shares.

    About Tarena International Inc.

    Tarena International Inc. is an online education service providing company that specifically focuses along with its subsidiaries on the provision of full-time and part0time classes. The classes take place under the Tarena brand and target the market in the People’s Republic of China. The company has two segments through which it operates; one targets the Adults in Adult Training program and the other targets Kids in the Kid Training program. The company also provides information technology related courses specifically for 7 courses such as Java, Linux, Big Data, Web front-end development, software testing, Python, and network engineer courses. What’s more, there are 3 non-IT subjects, including computerized workmanship, online deals and promoting, PC based plan flows through live distance guidance, and special visualizations VFX, just as homeroom based coaching and web based learning modules. It additionally gives 7 K-12 instruction programs for kids, including PC coding and advanced mechanics programming courses under the TongchengTongmei brand. What’s more, the organization extends to internet learning stage for schooling courses and employment opportunity arrangement instructional classes. As of December 31, 2020, it’s anything but an organization of 104 straightforwardly oversaw learning focuses in 45 urban communities; and 236 TongchengTongmei independent learning places in 53 urban areas. The organization was established in 2002 and is settled in Beijing, the People’s Republic of China.

    Why is Tarena facing so many lawsuits?

    TEDU stock is facing investigational lawsuits. These lawsuits usually are associated with the release of financial reports which have discrepancies in reporting, or with mergers and bankruptcies. In this case, TEDU stock’s release of financial results for the first quarter of 2021 is the cause of the lawsuits spree. The financial results gave an outlook for TEDU stock for the second quarter. In view of the Company’s current flow, absolute net incomes for the second quarter of 2021 are relied upon to be in the scope of RMB570.0 million and RMB600.0 million, subsequent to mulling over the occasional change factor and the probable proceeded with effect of the COVID-19. These estimations were susceptible to the current view and analysis of the company and external economy as well as events. However, this was not all that was susceptible in the company’s financial records;

    The lawsuits claim investigation on whether there is any misleading statements or hidden discrepancies that haven’t yet surfaced due to controversial financial or balance-sheet practices. The specific time for the investigation is when Tarana documented a Form NT 20-F Notification of failure to opportune record a Form 20-F for the fiscal year finished December 31, 2018, with the SEC on April 30, 2019. As per the Company, the postponement in recording was brought about by the autonomous review council of the registrant’s directorate, leading a survey of specific issues recognized over the span of the review of the registrant’s budget summaries for the year finished December 31, 2018, including issues identified with the registrant’s income acknowledgment. The Company then, at that point declared on November 1, 2019, that its financial reports from 2014-2018 couldn’t be depended on because of mistakes, related-party exchanges, and impedance with the review interaction. In view of this news, Tarena ADSs dropped by over 9% on November 4, 2019.

  • Why Inovio Pharmaceuticals, Inc. (INO) stock is rising in the Pre-Market today?

    Why Inovio Pharmaceuticals, Inc. (INO) stock is rising in the Pre-Market today?

    Shares of Inovio Pharmaceuticals, Inc. (INO) stock were rising in the pre-market trading session today after dropping as much as 30% during the last trading session. INO price saw a push of  0.58% to reach $6.89 a share at the time of this writing. INO dropped by 24.97% at the previous closing with a $6.85 per share price. Let’s see the reason behind this bull.

    What’s happening?

    Today’s bullish sentiment has nothing to do with any good news related to INO stock. There are no signs of analyst upgrades or increased targeted per share price of the INO to justify the rising behavior of INO stock. However, INO stock faced a massive drop of 30% during the last trading session after the announcement on Friday, April 23, 2021, that it’s funding for late-stage study testing of COVID-19 vaccine candidate has been stopped by the U.S  government due to the excessive availability of authorized vaccine in the country. However, funding for the ongoing mid-stage study testing will continue for the vaccine candidate of INO by the U.S government.

    The stopping of the fund for the late-stage study testing of a COVID-19 vaccine candidate resulted from the changing environment of COVID-19 amid the rapid development of vaccines and does not reflect the awardee or product. Moreover, this decision is also not a reflection of any data released for the INO-4800 vaccine. INO stock will continue to perform other operations with the U.S. government without any effect.

    Inovio is planning for a late-stage global study with its global collaborators INOVIO’s China partner, Advaccine, and the International Vaccine Institute (IVI,) based on the upcoming results related to safety and immunogenicity from mid-stage trial.

    Inovio Pharmaceuticals, Inc:

    Inovio Pharmaceuticals, Inc is a biotechnology company focused on the treatment of human papillomavirus (HPV) related diseases via the development of DNA medicines. INO stock has also been working on the development and commercialization of medicines to treat cancer and various infectious diseases. INO stock having a market cap of 1.908B was founded in 1979  and its headquarters is in Plymouth Meeting, Pennsylvania.

    Conclusion:

    The INO stock price is rising in the stock market today despite the absence of any good news related to it.INO stock experienced a massive drop in the previous trading session. Sometimes investors take it as the opportunity to purchase shares of a particular stock at a lower price considering the long-term benefits. In short deep fundamental and technical analysis is necessary before adding INO stock to the portfolio.